Core Viewpoint - The upcoming week will see a significant unlocking of shares, with a total market value exceeding 79 billion yuan, which may impact stock prices and market dynamics [6]. Group 1: Company Performance - Northern Rare Earth announced a forecast for the first three quarters of 2025, expecting a net profit attributable to shareholders of 1.51 billion to 1.57 billion yuan, representing a year-on-year increase of 272.54% to 287.34% [2]. - The company has implemented measures to enhance budget management, reduce costs, and improve efficiency, leading to a substantial increase in the production and sales volume of its main products [2]. - Northern Rare Earth adjusted the trading price of rare earth concentrate for Q4 2025 to 26,205 yuan/ton, reflecting a 37.13% increase from the previous quarter's price of 19,109 yuan/ton [2]. Group 2: Stock Unlocking Events - A total of 40 stocks will face unlocking next week, with a combined market value of over 79 billion yuan based on the latest closing prices [6]. - Notable stocks include China Merchants Port, which will have 577 million shares unlocked, amounting to a market value of 11.967 billion yuan, and Meihua Medical, with 412 million shares unlocking, valued at 9.804 billion yuan [6]. - The unlocking pressure is relatively lower for stocks like Xinkai Technology and Dingyang Technology, with unlocking values below 100 million yuan [6]. Group 3: Institutional Attention - Among the stocks facing unlocking, the average price increase since September is 4.66%, with Demingli leading at a 109.92% increase [7]. - Companies like Ruide Intelligent and Shenghui Integration have received significant institutional attention, with Ruide Intelligent reporting 50 institutional surveys and a market value of 5.93 billion yuan facing unlocking [7]. - Shenghui Integration is optimistic about its performance in the second half of the year, particularly in semiconductor and high-end panel production, leveraging its strong technical foundation and customer resources [7]. Group 4: Financial Performance of Unlocking Stocks - Several stocks facing unlocking, including Haichuang Pharmaceutical-U and Zhongke Jincai, reported losses in the first half of the year [8]. - In contrast, companies like China Merchants Port and Dongfang Electric reported net profits exceeding 1 billion yuan in the same period [8].

Core Insights - The 10th Pharmaceutical Innovation and Investment Conference will be held on October 26-27, 2025, in Nanjing, focusing on global pharmaceutical frontiers and capital trends, gathering top minds in the pharmaceutical innovation and investment fields [1][2]. Conference Information - The conference will take place at Fengda International Hotel, Nanjing, and will cover multiple thematic forums including innovative drug research and development, clinical research, cell and gene therapy, investment mergers and acquisitions, capital markets, and commercial insurance policies [2]. - The agenda includes various sub-forums such as cell and gene therapy, weight loss innovation, clinical data, anti-tumor new drugs, and international roadshows, ensuring comprehensive coverage of the pharmaceutical industry [3][4]. Key Topics - The conference will address core challenges and development trends in the pharmaceutical industry, emphasizing internationalization, investment financing, and regulatory policies, with a focus on the synergy between basic medical insurance and commercial health insurance [5]. - Discussions will include the strategies of Chinese innovative pharmaceutical companies in global markets, particularly in terms of licensing, mergers, and new investment trends [5][6]. Expert Participation - The conference will feature senior experts, clinical specialists, industry leaders, and frontline investors who will share insights on breakthrough technologies, practical experiences in investment mergers, and policy interpretations [4][6]. - Notable speakers include leaders from prestigious institutions and companies, contributing to discussions on the construction of innovative ecosystems and cross-sector collaboration [4][6]. Forum Structure - The conference will be structured around multi-dimensional forums designed to promote deep dialogue and knowledge sharing across clinical, industrial, capital, and policy fields, with three core discussion directions: global strategic layout, capital collaborative innovation, and market trend outlook [6].

数据来源：国家统计局，智研咨询整理 知前沿，问智研。智研咨询是中国一流产业咨询机构，十数年持续深耕产业研究领域，提供深度产业研 究报告、商业计划书、可行性研究报告及定制服务等一站式产业咨询服务。专业的角度、品质化的服 务、敏锐的市场洞察力，专注于提供完善的产业解决方案，为您的投资决策赋能。 2025年1-8月，四川省工业企业数（以下数据涉及的工业企业，均为规模以上工业企业，从2011年起， 规模以上工业企业起点标准由原来的年主营业务收入500万元提高到年主营业务收入2000万元）为19877 个，和上年同期相比，增加了1085个，同比增长5.77%，占全国的比重为3.81%。 2016-2025年1-8月四川省工业企业数统计图 上市公司：国城矿业（000688），德龙汇能（000593），ST升达（002259），成都燃气（603053）， 金石亚药（300434），达威股份（300535），侨源股份（301286），圣诺生物（688117），海创药业 （688302），大西洋（600558），秦川物联（688528），优机股份（833943），中寰股份（836260）佳 缘科技（301117），川能动力（0 ...

10月9日，海创药业跌0.94%，成交额7354.03万元。两融数据显示，当日海创药业获融资买入额944.32 万元，融资偿还1217.59万元，融资净买入-273.27万元。截至10月9日，海创药业融资融券余额合计3.35 亿元。 机构持仓方面，截止2025年6月30日，海创药业十大流通股东中，鹏华医药科技股票A（001230）位居 第二大流通股东，持股364.21万股，相比上期减少11.95万股。 融资方面，海创药业当日融资买入944.32万元。当前融资余额3.35亿元，占流通市值的7.78%，融资余 额超过近一年90%分位水平，处于高位。 责任编辑：小浪快报 融券方面，海创药业10月9日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量0.00股，融券余额0.00元，超过近一年80%分位水平，处于高位。 资料显示，海创药业股份有限公司位于四川省成都市高新区科园南路5号蓉药大厦1栋4层附2,3号，成立 日期2013年2月5日，上市日期2022年4月12日，公司主营业务涉及基于氘代技术和PROTAC靶向蛋白降 解等技术平台,以开发具有重大临床需求的Best-in-cla ...

Core Insights - Targeted protein degradation technology has seen significant development in China, providing new strategies for treating diseases such as cancer, neurodegenerative diseases, and autoimmune diseases [1][8] - The market size for targeted protein degradation in China is projected to reach approximately 102 million yuan in 2024, reflecting a year-on-year growth of 112.50% [1][8] - The increasing demand for novel drugs is driven by an aging population and the rise of chronic diseases, highlighting the technology's potential to meet unmet clinical needs [1][8] Industry Overview - Targeted protein degradation involves hijacking cellular degradation mechanisms to specifically degrade target proteins, addressing diseases caused by protein accumulation or dysfunction [2][4] - The technology overcomes limitations of traditional small molecule inhibitors, enabling the targeting of "undruggable" proteins [2][4] Industry Development History - The industry has evolved over two decades, starting from basic research to global competition, with significant milestones including the introduction of PROTAC concepts and the establishment of early technology platforms [4][5] - Recent years have seen a surge in clinical trials and the establishment of a robust pipeline, with 35 clinical programs reported as of 2024 [4][5] Industry Value Chain - The upstream of the industry includes raw materials such as E3 ubiquitin ligase ligands and various production equipment [5][6] - The midstream focuses on research and development, while the downstream applications target oncology and neurodegenerative diseases [5][6] Key Companies and Performance - Leading companies in the PROTAC space include HaiChuang Pharmaceutical and KaiTou Pharmaceutical, with significant clinical advancements in prostate and breast cancer treatments [8][10] - Jiangsu Hengrui Medicine has adopted a "fast-follow + innovation" strategy, achieving a 22.63% increase in revenue in 2024 [10][11] Industry Trends - Continuous technological innovation is expected to break through core technical bottlenecks in PROTAC, molecular glue, and LYTAC/AUTAC technologies [12][13] - The market is expanding into rare disease applications, with targeted protein degradation strategies being developed for conditions like Alzheimer's disease [13] - The industry ecosystem is being restructured with deepening international collaborations, positioning China as a key player in global biopharmaceutical innovation [14]

Core Insights - The ALS (Amyotrophic Lateral Sclerosis) drug development landscape in China is evolving, with significant advancements in research and clinical trials, but challenges remain in funding and commercialization [1][2][9] Group 1: Drug Development Progress - The first "cause-targeted" ALS drug, Tofersen, has been approved in China, filling a gap for SOD1-ALS patients and aligning domestic treatment options with international standards [2][3] - Multiple ASO (Antisense Oligonucleotide) therapies are in early clinical stages, including Ionis Pharmaceuticals' Ulefnersen, and domestic companies like Zhongmei Ruikang are developing siRNA therapies [3][4] - Since 2025, there have been numerous drug development advancements in the ALS field in China, with at least 15 new drug candidates reported [6][7] Group 2: Funding Challenges - The ALS drug development sector is primarily driven by small and medium-sized enterprises, facing significant funding challenges due to the high costs and risks associated with early-stage research [9][10] - Initial funding for ALS projects is often reliant on external investments, as many startups lack mature products to generate revenue [10][11] - Despite the overall interest in innovative drugs, the ALS sector has seen limited large-scale financing, with only a few companies achieving significant funding rounds [10][12] Group 3: Research and Regulatory Environment - The complexity of ALS, including unclear etiology and heterogeneous patient populations, complicates drug development and increases the risk of early-stage failures [11][12] - Companies are advocating for improved regulatory frameworks to expedite drug approvals and support for rare disease research, including tax incentives and the establishment of specialized funds [12][13] - Collaborative efforts are suggested to create national registries and databases to enhance research and data sharing among stakeholders [12][13]

Core Viewpoint - Shanghai Fosun Pharmaceutical's subsidiary, Fuhong Hanlin, has received approval from the National Medical Products Administration to conduct clinical trials for HLX43 in combination with HLX07 for the treatment of advanced/metastatic solid tumors [1] Group 1: Clinical Trials and Drug Development - The clinical trials will be conducted domestically, focusing on Phase Ib/II studies [1] - HLX43 is a targeted PD-L1 antibody-drug conjugate, while HLX07 is an innovative biopharmaceutical targeting the EGFR [1] - As of September 30, 2025, multiple clinical studies for HLX43 are being conducted globally, and several Phase II clinical studies for HLX07 are underway in China [1] Group 2: Financial Investment and Market Context - Cumulative research and development investment for this treatment regimen has reached approximately 150,000 yuan as of August [1] - There are currently no similar combination therapies approved for market globally [1]

Core Insights - The seventh Health China-Sinan Dialogue focused on biomedicine innovation and international cooperation, gathering representatives from various sectors to explore new paths for industry development [1][4] - The Huangpu District aims to strengthen the Guangci-Sinan Park's platform functions, establishing a modern industrial system centered on digital technology and life health [1][5] Group 1: Key Initiatives and Collaborations - Eight major announcements and signing ceremonies were held, covering ecological construction, talent assurance, and technological innovation [2] - The Guangci-Sinan (Zhongganghui) Medical Transformation Innovation Ecosystem was launched in collaboration with Ruijin Hospital, marking a significant step in Shanghai's talent retention policies [2] - The establishment of a "Medical Device and Biotechnology Verification Center" in partnership with Weigao Medical and Noripharma aims to create a collaborative innovation mechanism driven by clinical needs [2] Group 2: Technological Advancements - The "AI + Digital Health Technology Pilot Platform" was introduced, focusing on AI applications in science, medicine, and health, leveraging a reliable medical model [2] - A "Tumor Diagnosis and Treatment Innovation Incubator" was signed, attracting multiple biopharmaceutical companies to enhance the park's industrial ecosystem [2] Group 3: Industry Growth and Future Plans - The Guangci-Sinan Park has attracted approximately 283 companies with a total registered capital of about 2.9 billion, becoming a key platform for the efficient integration of innovative elements [5] - Future plans include leveraging the Huangpu District's "Central Science and Technology Innovation Zone" strategy to support the biomedical industry's innovation and transformation [5]

证券日报网讯 9月26日晚间，海创药业发布公告称，本次股票上市类型为首发限售股份；股票认购方式 为网下，上市股数为17，500，478股。本次股票上市流通总数为17，500，478股。本次股票上市流通日 期为2025年10月13日（因2025年10月12日为非交易日，故顺延至下一交易日）。 （编辑 楚丽君） ...

证券代码：688302 证券简称：海创药业 公告编号：2025-040 海创药业股份有限公司 首次公开发行部分限售股上市流通公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为首发限售股份；股票认购方式为网下，上市股数为 17,500,478股。 本次股票上市流通总数为17,500,478股。 本次股票上市流通日期为2025 年 10 月 13 日（因 2025 年 10 月 12 日为非 交易日，故顺延至下一交易日）。 一、本次上市流通的限售股类型 根据中国证券监督管理委员会于 2022 年 1 月 28 日出具的《关于同意海创药 业股份有限公司首次公开发行股票注册的批复》（证监许可〔2022〕250 号），同意 海创药业股份有限公司（以下简称"公司"或"海创药业"）首次公开发行股票的 注册申请。公司首次向社会公众公开发行人民币普通股（A 股）股票 24,760,000 股，并于 2022 年 4 月 12 日在上海证券交易所科创板上市交易。发行完成后总股 本为 99,015,598 ...